Aquastatin A, produced by Fusarium sp., is an inhibitor of mammalian adenosine triphosphatases with an IC50 of 7.1 µM against Na+/K+-ATPase 6.2 µM against H+/K+-ATPase. Aquastatin A is a potent inhibitor of enoyl-ACP reductase (FabI) of Staphylococcus aureus and is active against MRSA. Aquastatin A was patented for the treatment of gastric ulcers in 1994.